Lipid profile and renal safety of tenofovir disoproxil fumarate-based anti-retroviral therapy in HIV-infected Chinese patients
Open Access
- 1 June 2019
- journal article
- research article
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 83, 64-71
Abstract
No abstract availableKeywords
Funding Information
- Shanghai Municipal Key Clinical Specialty
- Shanghai Municipal Commission of Health and Family Planning (20164Y0015)
- Program for the 13th Five-year Plan of China (2017ZX10202101004)
This publication has 42 references indexed in Scilit:
- Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter studyBMC Infectious Diseases, 2013
- Switching to Tenofovir/Emtricitabine from Abacavir/ Lamivudine in HIV-Infected Adults with Raised Cholesterol: Effect on Lipid ProfilesAntiviral Therapy, 2012
- Prevention of HIV-1 Infection with Early Antiretroviral TherapyNew England Journal of Medicine, 2011
- Dyslipidemia in an HIV-Positive Antiretroviral Treatment-Naive Population in Dar es Salaam, TanzaniaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical careAIDS, 2011
- Lipid-lowering effect of tenofovir in HIV-infected patientsJournal of Antimicrobial Chemotherapy, 2010
- A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206AIDS, 2010
- Prevalence of Diabetes among Men and Women in ChinaNew England Journal of Medicine, 2010
- Modified Glomerular Filtration Rate Estimating Equation for Chinese Patients with Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2006
- Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovirAIDS, 2006